文献速递药物不良反应与药物警戒

因果关系评估对安全信号自动检测的贡献:法国药物警戒数据库示例

Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
PubMed 文献 · Drug Saf · 2020-01-01

本研究评估因果关系评估在自动安全信号检测中的潜在价值,基于法国药物警戒数据库2011至2017年所有再激发阳性且提示药物因果关系的药物-严重不良事件对,并与自动不成比例分析及WHO-UMC验证信号列表比较。155对感兴趣信号中115对(74.2%)也被其他信息来源识别,23个不良事件被加入药品说明书(其中7个未被不成比例分析识别),40对未被任何其他来源识别(其中13个经专家分析被视为潜在新安全信号)。因果关系评估识别的信号尤以抗肿瘤和免疫调节药物为主,可作为安全信号检测的补充工具。

要点

  • 因果关系评估可补充自动不成比例分析,用于药物安全信号检测。
  • 再激发阳性且提示因果关系的信号中,74.2%也被其他信息来源识别。
  • 该方法尤其有助于识别抗肿瘤和免疫调节药物的安全信号。

核心结论

  • 因果关系评估方法可作为安全信号检测的附加工具,尤其适用于抗肿瘤和免疫调节药物。

研究设计与样本

  • 研究基于法国药物警戒数据库(BNPV)2011至2017年数据,识别所有再激发阳性且提示药物因果关系的药物-严重不良事件对。
  • 结果与BNPV/WHO VigiBase®自动不成比例分析及WHO-UMC验证信号列表比较,并以药品说明书、Martindale®、Meyler's®和MedLINE®作为其他信息来源。

主要发现

  • 155对感兴趣信号中,115对(74.2%)也被另一信息来源识别。
  • 自BNPV个案报告以来,23个(14.8%)不良事件被加入药品说明书,其中7个未被不成比例分析识别。
  • 40对未被任何其他信息来源识别,其中13个经药物警戒专家分析个案报告后被视为潜在新安全信号。
  • 与WHO-UMC或BNPV内不成比例分析识别的信号相比,因果关系评估识别的信号尤其涉及抗肿瘤和免疫调节药物。

临床怎么用

  • 在自动不成比例分析之外,可结合因果关系评估(如再激发阳性且提示药物因果关系)辅助识别安全信号。
  • 对因果关系评估提示而定量分析未识别的信号,可进一步由药物警戒专家分析个案报告以判断潜在新安全信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Qualitative approaches based on drug causality assessment estimate the causal link between a drug and the occurrence of an adverse event from individual case safety reports. Quantitative approaches based on disproportionality analyses were developed subsequently to allow automated statistical signal detection from pharmacovigilance databases. This study assessed the potential value of causality assessment for automated safety signal detection. METHODS: All drug-serious adverse event pairs with a positive rechallenge and a semiology suggestive of drug causality were identified in the French pharmacovigilance database (BNPV) from 2011 to 2017. The results were compared with those obtained from automated disproportionality analyses of the BNPV/World Health Organization (WHO) VigiBase®, complemented by the list of signals validated by the WHO-UMC (Uppsala Monitoring Centre). Summary of Product Characteristics (SmPCs), Martindale®, Meyler's® and MedLINE® were used as other sources of information for the purpose of comparison. RESULTS: Of the 155 pairs of interest, 115 (74.2%) were also identified by another source of information. Since the individual case reporting in the BNPV, 23 (14.8%) of the adverse events (AEs) have been added to the SmPC, seven of which were not identified by disproportionality. Finally, 40 pairs were not identified by any other source of information, 13 of which were considered as potential new safety signals after analysis of case reports by pharmacovigilance experts. The signals identified by causality assessment involved antineoplastic and immunomodulatory drugs especially, in comparison with signals identified by WHO-UMC or by disproportionality within the BNPV. CONCLUSION: The approach therefore appears useful as an additional tool for safety signal detection, especially for antineoplastic and immunomodulating agents.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Berbain T, Pariente A, Miremont-Salamé G, et al. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database. Drug Saf. 2020. PMID: 31974775. doi:10.1007/s40264-019-00887-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。